The following sections describe the recent research and development of natural compounds targeting the PI3K/AKT/mTOR signaling pathway in lung cancer, particularly new natural compounds that are currently in the preclinical stages of development (Table 2). This evidence concerns the gene AKT1 and lung cancer.